Potential cisapride-erythromycin interaction
MG Tierney | TL Uhthoff | S Kravcik | AT Wielgosz
Cisapride is a relatively new drug that has potential for widespread use as a gastrokinetic agent. There have been rare reports of cisapride-induced QT prolongation with or without torsades de pointes ventricular tachycardia. The potential for this reaction may be enhanced by certain drug interactions involving the cytochrome P450 3A4 enzyme. Two cases of cisapride cardiotoxicity in association with erythromycin therapy are described and discussed. Further investigation is required to verify this interaction and to assess its incidence, mechanism and severity.